Biomemory acquired Catalog Technologies in March 2026 for undisclosed terms, saying the deal would accelerate its goal of becoming the first DNA data-storage provider deployed in data centers; the combined company said its first commercial solution is planned for the second half of 2026, and external coverage also notes a targeted H2 2026 launch window.
Technically, the move signals a shift from lab-scale DNA storage toward rackable, enterprise-integrated archival systems for high-value cold data, with stated use cases including long-term archives, regulated records, AI training datasets, compliance records, and critical backups; Biomemory and partners have also framed the medium as a durable archive tier with retention claims reaching roughly 150 years under suitable conditions.
For the Ark, this is a priority watch item for off-grid knowledge preservation: track whether Biomemory delivers a deployable, low-power archival appliance with standard data-center interfaces, test DNA archive viability against radiation, vacuum, temperature cycling, and maintenance limits, and evaluate whether it can serve as a deep-time mirror for essential scientific, medical, and governance records.